食管癌根治性放化疗中质子束治疗与调强放疗的疗效比较
本研究回顾性分析343例接受根治性放化疗的食管癌患者,其中质子束治疗132例、调强放疗211例。质子束治疗组总生存、无进展生存、无远处转移生存均显著优于调强放疗组,且毒性无差异;III期患者5年OS和PFS在质子组更高,但需前瞻性研究确认。
要点
- 质子束治疗组总生存、无进展生存、无远处转移生存均优于调强放疗组。
- 两组治疗相关毒性发生率无显著差异。
- III期患者质子组5年OS和PFS显著更高,I/II期无差异。
核心结论
- 与调强放疗相比,质子束治疗可能改善食管癌患者的总生存、无进展生存和局部区域无失败生存,尤其局部晚期患者。
研究设计与样本
- 回顾性单中心分析2007至2014年343例接受根治性放化疗的食管癌患者,质子束治疗132例,调强放疗211例。
主要发现
- 质子束治疗组总生存优于调强放疗组(P=.011)。
- 质子束治疗组无进展生存优于调强放疗组(P=.001)。
- 质子束治疗组无远处转移生存优于调强放疗组(P=.031)。
- 局部区域无失败生存质子组仅边缘优于调强组(P=.075)。
- 多因素分析中调强放疗组总生存(HR 1.454;P=.01)、无进展生存(HR 1.562;P=.001)和局部区域无失败生存(HR 1.461;P=.041)均差于质子组。
关键数值与推荐
- III期患者质子组5年总生存率34.6% vs 25.0%(P=.038)。
- III期患者质子组5年无进展生存率33.5% vs 13.2%(P=.005)。
- I/II期患者两组生存无显著差异。
- 两组治疗相关毒性发生率无显著差异。
临床怎么用
- 对于局部晚期食管癌,质子束治疗可能作为根治性放化疗的优选放疗技术,但需前瞻性研究验证。
局限性
- 回顾性单中心设计,年龄和种族因素组间未完全平衡。
- 结果需前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare clinical outcomes between proton beam therapy (PBT) and intensity modulated radiation therapy (IMRT) in patients with esophageal cancer (EC) treated with definitive chemoradiotherapy (CRT). METHODS AND MATERIALS: From 2007 through 2014, 343 EC patients who received definitive CRT with either PBT (n=132) or IMRT (n=211) were retrospectively analyzed. Survival, recurrence, and treatment toxicity were compared between groups. A Cox proportional hazards regression model was performed to test the association between patient/treatment variables and survival. RESULTS: Patient/treatment variables were overall well balanced, except for age and race. Compared with IMRT, PBT had significantly better overall survival (OS; P=.011), progression-free survival (PFS; P=.001), distant metastasis-free survival (DMFS; P=.031), as well as marginally better locoregional failure-free survival (LRFFS; P=.075). No significant differences in rates of treatment-related toxicities were observed between groups. On multivariate analysis, IMRT had worse OS (hazard ratio [HR] 1.454; P=.01), PFS (HR 1.562; P=.001), and LRFFS (HR 1.461; P=.041) than PBT. Subgroup analysis by clinical stage revealed considerably higher 5-year OS (34.6% vs 25.0%, P=.038) and PFS rates (33.5% vs 13.2%, P=.005) in the PBT group for patients with stage III disease. However, no significant intergroup differences in survival were identified for stage I/II patients. CONCLUSIONS: Compared with IMRT, PBT might be associated with improved OS, PFS, and LRFFS, especially in EC patients with locally advanced disease. These results need confirmation by prospective studies.
引用
- Xi M, Xu C, Liao Z, et al. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017. PMID: 29280461. doi:10.1016/j.ijrobp.2017.06.2450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。